Couvée Jaap E, Zitman Frans G
Medical Department, GlaxoSmithKline, Zeist, The Netherlands.
Addiction. 2002 Mar;97(3):337-45. doi: 10.1046/j.1360-0443.2002.00081.x.
The Benzodiazepine Withdrawal Symptom Questionnaire (BWSQ, Tyrer et al. 1990) has been developed to measure distinct features of the benzodiazepine withdrawal syndrome. However, psychometric evaluations of this questionnaire are scarce. AIMS, SETTING: To evaluate the BWSQ during a discontinuation program carried out by general practitioners in 230 depressed chronic benzodiazepine users.
Reliability coefficients during the program were between 0.84 and 0.88 and the test-retest correlations were between 0.75 and 0.88 during withdrawal. Mean scores of the BWSQ during withdrawal differentiated between completers and failures (p = 0.036). The factor structure underlying the items consisted of perceptual and sensory disturbances, dysphoric mood, muscular pain and memory loss. Low scores during the last phase of tapering off predicted no, or limited, use of benzodiazepines in the first years following discontinuation (p = 0.003).
We found the BWSQ to measure symptoms during benzodiazepine withdrawal in a reliable way. Our findings indicate some construct validity for BWSQ. Low scores during withdrawal predict more limited future use of benzodiazepines.
苯二氮䓬戒断症状问卷(BWSQ,泰勒等人,1990年)已被开发用于测量苯二氮䓬戒断综合征的不同特征。然而,对该问卷的心理测量学评估很少。目的、背景:在230名抑郁的慢性苯二氮䓬使用者中,由全科医生开展一项停药计划,以评估BWSQ。
该计划期间的信度系数在0.84至0.88之间,戒断期间的重测相关性在0.75至0.88之间。戒断期间BWSQ的平均得分在完成者和未完成者之间存在差异(p = 0.036)。项目背后的因子结构包括感知和感觉障碍、烦躁情绪、肌肉疼痛和记忆力丧失。逐渐减量最后阶段的低分预示着停药后的头几年不会使用或有限使用苯二氮䓬(p = 0.003)。
我们发现BWSQ能够可靠地测量苯二氮䓬戒断期间的症状。我们的研究结果表明BWSQ具有一定的结构效度。戒断期间的低分预示着未来苯二氮䓬的使用将更有限。